Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,483 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT07734441RecruitingEarly Phase 1
Itraconazole vs Ketoconazole for Scalp Seborrheic Dermatitis
This study compares two treatments—itraconazole pills and ketoconazole shampoo—for moderate to severe dandruff on the scalp. It aims to find which works better for teens aged 14–17.
Chak Four Hundred Fifty-four, Punjab ProvinceAges 18–65 - NCT07301255RecruitingPhase 2
ENV-294 for moderate-to-severe asthma in adults
This trial tests an experimental drug called ENV-294 in adults with moderate-to-severe asthma. You may join if you are already using two kinds of inhalers regularly and have had at least one asthma flare-up in the past year that needed steroids or a hospital visit.
Birmingham, AlabamaAges 18–75 - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT07207954RecruitingPhase 1
Testing LFD-200 in healthy adults and adults with rheumatoid arthritis
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
MelbourneAges 18–75 - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Peoria, ArizonaAges 18 years+ - NCT06316297RecruitingPhase 1/Phase 2
Testing a new mRNA vaccine for moderate to severe acne
This study tests an experimental mRNA vaccine designed to help the immune system fight acne-causing bacteria. It's for adults with moderate or severe facial acne who are otherwise healthy, and it may offer a new way to treat acne beyond typical creams or pills.
Scottsdale, ArizonaAges 18–45 - NCT07413172RecruitingPhase 2
Testing serum tears for severe dry eye
This study tests whether eye drops made from your own blood serum (with a natural lubricant) can relieve moderate-to-severe dry eye better than a standard salt solution. If you have dry eye from certain immune conditions or nerve damage, this may help find a more effective treatment.
Miami, FloridaAges 18 years+ - NCT07723144Recruiting
Identifying sleep apnea biomarkers
This study compares blood samples from people with moderate-to-severe sleep apnea and those without sleep apnea to find markers that could help diagnose or treat the condition. Half of those with sleep apnea will start CPAP therapy right away, while others wait before starting.
Bialystok, Podlaskie VoivodeshipAges 18–65 - NCT07721441Enrolling by invitation
Predicting Gut Healing in Ulcerative Colitis with a Stool Test
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06899204Recruiting
Abrocitinib for atopic dermatitis after biologic therapy
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
San Diego, CaliforniaAges 12 years+ - NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT06807268RecruitingPhase 3
A study of abrocitinib for children ages 6–11 with eczema
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
Birmingham, AlabamaAges 6–11 - NCT06807281RecruitingPhase 3
Abrocitinib for children with eczema: long-term study
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Birmingham, AlabamaAges 2–11 - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18 years+ - NCT07543419Recruiting
Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Ancona, ANAges 18–100 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Scottsdale, ArizonaAges 18–80 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Caba, Buenos AiresAges 18–100
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,483 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.